KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Resmed (RMD) Revenue (2016 - 2025)

Resmed (RMD) has disclosed Revenue for 17 consecutive years, with $1.4 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue rose 10.98% year-over-year to $1.4 billion, compared with a TTM value of $5.4 billion through Dec 2025, up 9.57%, and an annual FY2025 reading of $5.1 billion, up 9.84% over the prior year.
  • Revenue was $1.4 billion for Q4 2025 at Resmed, up from $1.3 billion in the prior quarter.
  • Across five years, Revenue topped out at $1.4 billion in Q4 2025 and bottomed at $768.8 million in Q1 2021.
  • Average Revenue over 5 years is $1.1 billion, with a median of $1.1 billion recorded in 2023.
  • The sharpest move saw Revenue decreased 0.09% in 2021, then grew 29.2% in 2023.
  • Year by year, Revenue stood at $894.9 million in 2021, then rose by 15.52% to $1.0 billion in 2022, then increased by 12.48% to $1.2 billion in 2023, then rose by 10.26% to $1.3 billion in 2024, then rose by 10.98% to $1.4 billion in 2025.
  • Business Quant data shows Revenue for RMD at $1.4 billion in Q4 2025, $1.3 billion in Q3 2025, and $1.3 billion in Q2 2025.